WO2004007557A3 - Tf antagonist - Google Patents
Tf antagonist Download PDFInfo
- Publication number
- WO2004007557A3 WO2004007557A3 PCT/DK2003/000480 DK0300480W WO2004007557A3 WO 2004007557 A3 WO2004007557 A3 WO 2004007557A3 DK 0300480 W DK0300480 W DK 0300480W WO 2004007557 A3 WO2004007557 A3 WO 2004007557A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antagonist
- conjugates
- relates
- patho
- reperfusion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003242506A AU2003242506A1 (en) | 2002-07-12 | 2003-07-09 | Tf antagonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200201100 | 2002-07-12 | ||
DKPA200201100 | 2002-07-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004007557A2 WO2004007557A2 (en) | 2004-01-22 |
WO2004007557A3 true WO2004007557A3 (en) | 2004-04-22 |
Family
ID=30011020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2003/000480 WO2004007557A2 (en) | 2002-07-12 | 2003-07-09 | Tf antagonist |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003242506A1 (en) |
WO (1) | WO2004007557A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064870A2 (en) * | 2003-01-22 | 2004-08-05 | Novo Nordisk A/S | Radiolabelled tissue factor binding agent and the use thereof |
WO2005025623A2 (en) * | 2003-07-28 | 2005-03-24 | Emory University | Ef-24-factor vii conjugates |
GB2419774A (en) | 2004-10-27 | 2006-05-03 | Ericsson Telefon Ab L M | Accessing IP multimedia subsystem (IMS) services |
UA109633C2 (en) | 2008-12-09 | 2015-09-25 | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
WO2011069149A2 (en) | 2009-12-04 | 2011-06-09 | Dcb-Usa Llc | Cathepsin s inhibitors |
EP2582728B1 (en) * | 2010-06-15 | 2017-08-23 | Genmab A/S | Human antibody drug conjugates against tissue factor |
CN113521016A (en) * | 2013-11-21 | 2021-10-22 | 根马布股份公司 | Antibody-drug conjugate lyophilized formulation |
ES2856968T3 (en) | 2016-01-15 | 2021-09-28 | Rigshospitalet | Quantitative PET Imaging of Tissue Factor Expression Using 18F-Labeled Active Site Inhibited Factor VII |
US20190358351A1 (en) * | 2016-11-17 | 2019-11-28 | Minerva Imaging Aps | 177-lu labeled active site inhibited factor vii |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012800A1 (en) * | 1994-10-24 | 1996-05-02 | Zymogenetics, Inc. | Modified factor vii |
WO2000042973A2 (en) * | 1999-01-22 | 2000-07-27 | The Burnham Institute | Homing pro-apoptotic conjugates and methods of using same |
WO2001002439A1 (en) * | 1999-07-01 | 2001-01-11 | Yale University | Neovascular-targeted immunoconjugates |
WO2001021661A1 (en) * | 1999-09-20 | 2001-03-29 | Novo Nordisk A/S | BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX |
JP2001213804A (en) * | 2000-01-31 | 2001-08-07 | Chugai Pharmaceut Co Ltd | Antitissue factor antibody complex |
-
2003
- 2003-07-09 AU AU2003242506A patent/AU2003242506A1/en not_active Abandoned
- 2003-07-09 WO PCT/DK2003/000480 patent/WO2004007557A2/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012800A1 (en) * | 1994-10-24 | 1996-05-02 | Zymogenetics, Inc. | Modified factor vii |
WO2000042973A2 (en) * | 1999-01-22 | 2000-07-27 | The Burnham Institute | Homing pro-apoptotic conjugates and methods of using same |
WO2001002439A1 (en) * | 1999-07-01 | 2001-01-11 | Yale University | Neovascular-targeted immunoconjugates |
WO2001021661A1 (en) * | 1999-09-20 | 2001-03-29 | Novo Nordisk A/S | BIVALENT INHIBITOR OF FVIIa/TF/FXa COMPLEX |
JP2001213804A (en) * | 2000-01-31 | 2001-08-07 | Chugai Pharmaceut Co Ltd | Antitissue factor antibody complex |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch Week 200173, Derwent World Patents Index; Class B04, AN 2001-629603, XP002262305 * |
H. MICHAEL ELLERBY ET AL: "Anti-cancer activity of targeted pro-apoptotic peptides", NATURE MEDICINE, vol. 5, no. 9, September 1999 (1999-09-01), pages 1032 - 1038, XP002262304 * |
Also Published As
Publication number | Publication date |
---|---|
AU2003242506A1 (en) | 2004-02-02 |
WO2004007557A2 (en) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007011693A3 (en) | Compositions of placentally-derived stem cells for the treatment of cancer | |
WO2008039218A3 (en) | Inhibitors of bruton's tyrosine kinase | |
EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
EE200200578A (en) | Therapeutic combinations of antihypertensive and anti-angiogenic agents | |
WO2003094836A3 (en) | Methods and products for enhancing immune responses using imidazoquinoline compounds | |
AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
IL157656A (en) | Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes | |
DE60223254D1 (en) | DELAYED FORCULATING FORMULATIONS OF OXYMORPHONE | |
WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
TR200102733T2 (en) | Recombinant IL-18 antagonists useful in the treatment of IL-18 related disorders | |
AR034900A1 (en) | USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT | |
WO2002040702A3 (en) | Methods for the treatment of cancer and other diseases and methods of developing the same | |
IL167890A (en) | Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome | |
HUP0400548A2 (en) | Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma | |
DE69932510D1 (en) | VASKULARISIERUNGSINHIBITOREN | |
WO2005032470A3 (en) | Compositions and methods for treating burns | |
MXPA05011858A (en) | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use. | |
WO2004007557A3 (en) | Tf antagonist | |
WO2005042027A3 (en) | Antagonists of the bradykinin b1 receptor | |
WO2001076638A3 (en) | Compositions for drug delivery | |
EA200100799A1 (en) | ANTAGONISTS OF THE TUMOR NECROSE FACTOR AND THEIR APPLICATION IN ENDOMETRIOSIS | |
EA200200922A1 (en) | COMPOSITION INCLUDING CAMPLATOTICINE AND PYRIMIDINE DERIVATIVE FOR CANCER TREATMENT | |
BR0109515A (en) | Apomorphine Derivatives and Methods for Their Use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |